Predicting the extent of prostate cancer using the combination of systematic biopsy and serum prostate-specific antigen in Japanese men

BJU International

Volumn 83, Issue 1, 1999, Pages 39-42

  Gohji, K ^a   Okamoto, M ^a   Takenaka, A ^b   Nomi, M ^a   Fujii, A ^b  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

Japanese men; Organ confined disease; Prediction; Prostate cancer; PSA; Systematic biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; BIOPSY, NEEDLE; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0032990636     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00875.x     Document Type: Article

References (24)

1. 1 Wingo P, Tong T, Bolden S. Cancer Statistics. CA 1995; 45: 12
2. 2 Tominaga S, Aoki K, Hanai A, Kurihara N. Cancer Statistics incidence/mortality/prognosis, 1993. Shinohara Publishing Co., Tokyo, 1993: 154-70
3. 3 Oesterling JE, Kumamoto Y, Tsukamoto T et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995; 75: 347-53
4. 4 Gohji K, Nomi M, Egawa S et al. Detection of prostate cancer using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer 1997; 79: 1969-76
5. 5 Jewett HJ, Bridge RW, Gray GF Jr, Shelly WM. The palpable nodules of prostate cancer: results 15 years after radical excision. JAMA 1968; 203: 403-0
6. 6 Lee F, Torp-Pedersen ST, Littrup PJ et al. Hypoechoic lesion of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology 1989; 170: 29-32
7. 7 Mettlin C, Lee F, Drago J, Murphy GP and the investigators of the American Cancer Society National Prostate Cancer Detection Project. The American Cancer Society National Prostate Cancer Detection Project: findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949-58
8. 8 Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
9. 9 Carter HB, Coffey DS. Prostate cancer: the magnitude of the problem in the United States. In Coffey DS, Resnick MI, Door FA, Karr JP eds. A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. New York: Plenum Press, 1988: 1-7
10. 10 Partin AW, Carter HB, Chan DW et al. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-52
11. 11 Younes E, Haas GP, Montie JE, Smith JB, Powell IJ, Pontes JE. Value of preoperative PSA in predicting pathologic stage of patients undergoing salvage prostatectomy. Urology 1994; 43: 22-5
12. 12 Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus detected ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-5
13. 13 Gohji K, Morisue K, Kizaki T, Fujii A. Correlation of transrectal ultrasound imaging and the results of systematic biopsy with pathological examination of radical prostatectomy specimens. Br J Urol 1995; 75: 758-65
14. 14 Egawa S, Suyama K, Ohori M et al. Early detection of prostate cancer. Results of a prostate specific antigen based detection program in Japan. Cancer 1995; 76: 463-72
15. 15 Egawa S, Koh H, Satoh T et al. Preoperative serum prostate-specific antigen, clinical stage and Gleason sum as basis for predicting final pathological stage in Japanese prostate cancer. Jpn J Clin Oncol 1996; 26: 438-44
16. 16 International Union Against Cancer. In Sobin LH, Wittekind CH eds, TNM Classification of Malignant Tumors, 5th edn. New York: John Wiley & Sons, 1997: 170-3
17. 17 Terris MK, McNeal JE, Stanley TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992; 148: 829-32
18. 18 Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988; 139: 1235-41
19. 19 Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995; 153: 1543-8
20. 20 Wang X, Brannigan RE, Rademaker AW, McVary KT, Oyasu R. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. J Urol 1997; 158: 1431-5
21. 21 Narayan P, Cajendran V, Taylor SP et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995; 46: 205-12
22. 22 Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-4
23. 23 Bluestein DL, Bostwick DG, Bergstralh E, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994; 151: 1315-20
24. 24 Bostwick DG, Qian J, Bergstralh E et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155: 1361-7